USPTO serial 99328081
PKX BIO
Reviewed by CopyMark Law Group
Status 688Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- PURATH, ANICKA S
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with PKX BIO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,545*
Plus Government fees of $750
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
NEW YORK, NY, US
Santa Barbara, CA, US
Santa Barbara, CA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Aaron D. Hendelman
Aaron D. Hendelman WILSON SONSINI GOODRICH & ROSATI650 Page Mill RoadPalo Alto, CA 94304United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Industrial chemicals, namely, cyclodextrins for industrial purposes; chemical preparations derived from cyclodextrins, namely, chemicals for industrial purposes and active principles in the nature of active chemical ingredients, complexed by cyclodextrins, for use in the manufacture of pharmaceuticals and medicines; chemicals for use in industry, namely, cyclodextrins and cyclodextrin derivatives for use in the chemical, plastics, paper, agricultural, horticultural, insulation, packaging, pharmaceutical, cosmetic, fragrance, textile, leather, healthcare, food and paint industries; active pharmaceutical ingredients, namely, active chemical ingredients in the nature of salts for use in the manufacture of pharmaceuticals and medicines | ACTIVE | — |
| 005 | Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders | ACTIVE | — |
| 010 | Wearable drug delivery devices sold empty, namely, implantable subcutaneous drug delivery pumps for the delivery of medication for viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders | ACTIVE | — |
| 042 | Medical and scientific research in the fields of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; medical and scientific research and development in the field of pharmaceuticals and drug delivery platforms; providing scientific information, scientific research advisory, and scientific research consultancy in the field of pharmaceuticals and drug delivery devices therefor; pharmaceutical research and development; drug discovery services; computational biology research; research and development services in the fields of bioinformatics, genomics, biotechnology, immunology and pharmaceuticals; biomedical research services and biomedical development services being pharmaceutical drug development services; scientific study and research in the fields of medicine, biomedical technology, and genetics; technical consultancy in the field of scientific research relating to biotechnology and product development for others in the field of biotechnology; pharmaceutical drug development services | ACTIVE | — |
| 044 | Providing medical information, advisory, and consultancy services relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals and regarding the use of drug delivery devices therefor | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by PKX BIO, INC.
- Other trademarks owned by Bexson Biomedical, Inc.
- Other trademarks owned by Bexson Biomedical, Inc.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named PKX BIO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 21, 2026 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Sep 1, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 7, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 7, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 1, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 9, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 9, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 9, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 9, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 9, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 22, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 11, 2026 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 11, 2026 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 11, 2026 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 2, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 2, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 2, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 23, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 23, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 23, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 22, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 18, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 8, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 8, 2025 | NWAP | NEW APPLICATION ENTERED | — |